JP2003506095A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003506095A5 JP2003506095A5 JP2001515852A JP2001515852A JP2003506095A5 JP 2003506095 A5 JP2003506095 A5 JP 2003506095A5 JP 2001515852 A JP2001515852 A JP 2001515852A JP 2001515852 A JP2001515852 A JP 2001515852A JP 2003506095 A5 JP2003506095 A5 JP 2003506095A5
- Authority
- JP
- Japan
- Prior art keywords
- precursor
- dendritic cell
- antigen
- cytokine
- genetically modified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004443 dendritic cell Anatomy 0.000 description 65
- 108090000623 proteins and genes Proteins 0.000 description 48
- 239000002243 precursor Substances 0.000 description 46
- 239000000427 antigen Substances 0.000 description 43
- 108091007433 antigens Proteins 0.000 description 43
- 102000036639 antigens Human genes 0.000 description 43
- 238000000034 method Methods 0.000 description 39
- 102000004127 Cytokines Human genes 0.000 description 29
- 108090000695 Cytokines Proteins 0.000 description 29
- 230000026683 transduction Effects 0.000 description 17
- 238000010361 transduction Methods 0.000 description 17
- 230000001464 adherent effect Effects 0.000 description 15
- 239000002609 medium Substances 0.000 description 14
- 230000004663 cell proliferation Effects 0.000 description 11
- 241000701806 Human papillomavirus Species 0.000 description 9
- 230000004069 differentiation Effects 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 108010063738 Interleukins Proteins 0.000 description 6
- 102000015696 Interleukins Human genes 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 6
- 102000003390 tumor necrosis factor Human genes 0.000 description 6
- 230000002463 transducing effect Effects 0.000 description 5
- 230000004936 stimulating effect Effects 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 3
- 241000702421 Dependoparvovirus Species 0.000 description 3
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
- 241000711549 Hepacivirus C Species 0.000 description 3
- 241000700721 Hepatitis B virus Species 0.000 description 3
- 101001034314 Homo sapiens Lactadherin Proteins 0.000 description 3
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 description 3
- 108700005307 Human papillomavirus HPV L1 Proteins 0.000 description 3
- 108090000978 Interleukin-4 Proteins 0.000 description 3
- 102100039648 Lactadherin Human genes 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 102100038081 Signal transducer CD24 Human genes 0.000 description 3
- 210000000234 capsid Anatomy 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 231100000283 hepatitis Toxicity 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 241000700605 Viruses Species 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14726399P | 1999-08-05 | 1999-08-05 | |
| US60/147,263 | 1999-08-05 | ||
| PCT/US2000/021410 WO2001011067A1 (en) | 1999-08-05 | 2000-08-07 | Genetically altered dendritic cells transduced with adeno-associated virus (aav), methods of producing said cells and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003506095A JP2003506095A (ja) | 2003-02-18 |
| JP2003506095A5 true JP2003506095A5 (https=) | 2007-09-27 |
Family
ID=22520891
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001515852A Pending JP2003506095A (ja) | 1999-08-05 | 2000-08-07 | アデノ随伴ウイルス（ａａｖ）で形質導入された遺伝子改変樹状細胞、該細胞の調製方法および該細胞の使用 |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1206563B1 (https=) |
| JP (1) | JP2003506095A (https=) |
| AT (1) | ATE456662T1 (https=) |
| AU (1) | AU6894300A (https=) |
| CA (2) | CA2309313A1 (https=) |
| DE (1) | DE60043779D1 (https=) |
| WO (1) | WO2001011067A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ522840A (en) | 2000-06-01 | 2004-12-24 | Univ North Carolina | A parvovirus vector that carries a duplexed genome resulting in co-packaging of strands of plus and minus polarity tethered together |
| AU2003231281A1 (en) * | 2002-04-30 | 2003-11-17 | University Of Florida | Methods and compositions for expressing a nucleic acid in a dendritic cell |
| US20060239962A1 (en) * | 2002-12-04 | 2006-10-26 | Banchereau Jacques F | Rapid one-step generation of antigen loaded dendritic cell vaccine from precursors |
| SE0301109D0 (sv) * | 2003-04-14 | 2003-04-14 | Mallen Huang | Nucleotide vaccine composition |
| US9085807B2 (en) * | 2004-09-14 | 2015-07-21 | Argos Therapeutics, Inc. | Strain-independent amplification of pathogens and vaccines thereto |
| US8877206B2 (en) | 2007-03-22 | 2014-11-04 | Pds Biotechnology Corporation | Stimulation of an immune response by cationic lipids |
| CA2721366C (en) | 2008-04-17 | 2017-06-06 | Elizabeth Ann Vasievich | Stimulation of an immune response by enantiomers of cationic lipids |
| WO2013174760A1 (en) | 2012-05-25 | 2013-11-28 | Deutsches Krebsforschungszentrum | Optimized aav-vectors for high transduction rates in dendritic cells |
| CN105163753B (zh) | 2012-06-15 | 2018-12-21 | Pds生物科技公司 | 阳离子脂质疫苗组合物和使用方法 |
| CN105101991A (zh) | 2012-09-21 | 2015-11-25 | Pds生物科技公司 | 改进的疫苗组合物和使用方法 |
| WO2017083820A1 (en) | 2015-11-13 | 2017-05-18 | Pds Biotechnology Corporation | Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy |
| MA46959A (fr) | 2016-12-02 | 2019-10-09 | Juno Therapeutics Inc | Cellules b modifiées et compositions et méthodes associées |
| CA3084957A1 (en) | 2017-12-05 | 2019-06-13 | Pds Biotechnology Corporation | Methods and compositions comprising cationic lipids for stimulating type 1 interferon genes |
| MX2023004182A (es) * | 2020-10-15 | 2023-06-22 | Aavocyte Inc | Vectores de virus adenoasociados recombinantes con promotor de cumulo de diferenciacion 14 (cd14) y uso de los mismos. |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU6504596A (en) * | 1995-07-21 | 1997-02-18 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Adeno-associated viral liposomes and their use in transfecting dendritic cells to stimulate specific immunity |
| JP2000505650A (ja) * | 1996-02-08 | 2000-05-16 | アメリカ合衆国 | 樹状突起細胞を形質転換し、そしてｔ細胞を活性化するための方法及び組成物 |
| AU5588298A (en) * | 1996-12-02 | 1998-06-29 | Cell Genesys, Inc. | Adeno-associated viral vector-mediated delivery of dna to cells of the liver |
| ID27813A (id) * | 1998-01-28 | 2001-04-26 | Corixa Corp | Senyawa-senyawa untuk terapi dan diagnosa kanker paru-paru dan metoda untuk penggunaannya |
-
2000
- 2000-06-09 CA CA 2309313 patent/CA2309313A1/en not_active Abandoned
- 2000-08-07 WO PCT/US2000/021410 patent/WO2001011067A1/en not_active Ceased
- 2000-08-07 AU AU68943/00A patent/AU6894300A/en not_active Abandoned
- 2000-08-07 AT AT00957305T patent/ATE456662T1/de not_active IP Right Cessation
- 2000-08-07 DE DE60043779T patent/DE60043779D1/de not_active Expired - Lifetime
- 2000-08-07 CA CA 2381293 patent/CA2381293A1/en not_active Abandoned
- 2000-08-07 JP JP2001515852A patent/JP2003506095A/ja active Pending
- 2000-08-07 EP EP20000957305 patent/EP1206563B1/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003506095A5 (https=) | ||
| Giannini et al. | Cytokine expression in squamous intraepithelial lesions of the uterine cervix: implications for the generation of local immunosuppression | |
| Shi et al. | Granulocyte-macrophage colony-stimulating factor (GM-CSF) and T-cell responses: what we do and don't know | |
| Kikuchi et al. | Dendritic cells modified to express CD40 ligand elicit therapeutic immunity against preexisting murine tumors | |
| US9345754B2 (en) | Allogeneic tumor therapeutic agent, a vaccine using allogeneic tumor cells for the therapeutic treatment of tumor diseases, and a method for the making of such a vaccine, and transfected human tumor cells for use as a vaccine | |
| Gambotto et al. | Induction of antitumor immunity by direct intratumoral injection of a recombinant adenovirus vector expressing interleukin-12 | |
| JP2003510290A5 (https=) | ||
| Benencia et al. | Whole tumor antigen vaccination using dendritic cells: comparison of RNA electroporation and pulsing with UV-irradiated tumor cells | |
| JP2011036251A (ja) | ウイルスベクターおよびその遺伝子治療のための使用 | |
| JP2004538000A (ja) | 樹状突起細胞の成熟化の方法 | |
| TWI890893B (zh) | 用於人類乳突病毒的ｄｎａ疫苗及其使用方法 | |
| Zhao et al. | The role of mesenchymal stem cells in cancer immunotherapy | |
| JP2002528115A5 (https=) | ||
| Yo et al. | Coexpression of Flt3 ligand and GM-CSF genes modulates immune responses induced by HER2/neu DNA vaccine | |
| JP2025504109A (ja) | Ｅｂｖ複合抗原、樹状細胞ワクチンおよびその使用 | |
| Liu et al. | Dendritic cells engineered to express the Flt3 ligand stimulate type I immune response, and induce enhanced cytoxic T and natural killer cell cytotoxicities and antitumor immunity | |
| CN114807048A (zh) | 一种基因工程化的抗原提呈细胞外囊泡及其制备方法和应用 | |
| JP3822261B2 (ja) | 癌の遺伝子治療剤 | |
| Shin et al. | Tumor cells ectopically expressing the membrane-bound form of IL-7 develop an antitumor immune response efficiently in a colon carcinoma model | |
| Tanigawa et al. | Gene gun application in the generation of effector T cells for adoptive immunotherapy | |
| Triozzi et al. | Antitumor activity of the intratumoral injection of fowlpox vectors expressing a triad of costimulatory molecules and granulocyte/macrophage colony stimulating factor in mesothelioma | |
| Gitlitz et al. | Phase I trial of granulocyte macrophage-colony stimulating factor and interleukin-4 as a combined immunotherapy for patients with cancer | |
| JP2002500872A5 (https=) | ||
| Perez-Shibayama et al. | Dendritic cell-specific delivery of Flt3L by coronavirus vectors secures induction of therapeutic antitumor immunity | |
| EP0825873B1 (en) | Anticancer vaccine comprising il6/il6 receptor transfected cells |